These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12743072)

  • 21. Debate sparked over pharma-funded CME.
    Eggertson L
    CMAJ; 2016 Mar; 188(4):E65-E66. PubMed ID: 26833734
    [No Abstract]   [Full Text] [Related]  

  • 22. Continuing medical education and pharmaceutical industry.
    Vakani FS; Jafri W; Amin A; Sheerani M
    J Coll Physicians Surg Pak; 2011 Jun; 21(6):360-1. PubMed ID: 21711993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharma and CME: View from the US.
    Fletcher S
    BMJ; 2008 Aug; 337():a1023. PubMed ID: 18703647
    [No Abstract]   [Full Text] [Related]  

  • 24. American academy of pain medicine ethics council statement on conflicts of interest: interaction between physicians and industry in pain medicine.
    Dubois MY;
    Pain Med; 2010 Feb; 11(2):257-62. PubMed ID: 19930112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Businesses are buying the ethics they want.
    DeVries R
    Washington Post; 2004 Feb; ():B2. PubMed ID: 15580697
    [No Abstract]   [Full Text] [Related]  

  • 26. Industry support and professional medical associations.
    Ray WL; Addleton RL
    JAMA; 2009 Aug; 302(7):738; author reply 739. PubMed ID: 19690305
    [No Abstract]   [Full Text] [Related]  

  • 27. Finding the line: physicians, pharma, and drug development.
    Redig A
    Acad Med; 2009 Feb; 84(2):228-9. PubMed ID: 19174673
    [No Abstract]   [Full Text] [Related]  

  • 28. [Recomendaciones a los cuerpos directivos de las agrupaciones médicas en su relación con la industria].
    Soda A; Campillo C; Arrieta O; Burgos R; Celis MÁ; Llata M; Domínguez J; Halabe J; Islas S; Jasso L; Lifshitz A; Moreno M; Plancarte R; Reyes A; Ruiz-Argüelles GJ; Verástegui E; Sotelo J
    Gac Med Mex; 2018; 154(5):622-623. PubMed ID: 30407458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Keep medical education independent! It should not be a scene of drug industry marketing].
    Eliasson G; Håkansson J
    Lakartidningen; 2001 Sep; 98(39):4168-9. PubMed ID: 11680148
    [No Abstract]   [Full Text] [Related]  

  • 30. Treating desires not diseases: a pill for every ill and an ill for every pill?
    Triggle DJ
    Drug Discov Today; 2007 Feb; 12(3-4):161-6. PubMed ID: 17275737
    [No Abstract]   [Full Text] [Related]  

  • 31. Marketing Rx&D.
    Ogle K
    CMAJ; 2003 May; 168(10):1238-9; discussion 1239. PubMed ID: 12743055
    [No Abstract]   [Full Text] [Related]  

  • 32. The corporate co-author, the ghostwriter, and the medical society: an object lesson (June, 2005 issue).
    Goodman RL; Carrasquillo O
    J Gen Intern Med; 2006 Jan; 21(1):102. PubMed ID: 16423136
    [No Abstract]   [Full Text] [Related]  

  • 33. The speakers' bureau system: a form of peer selling.
    Reid L; Herder M
    Open Med; 2013; 7(2):e31-9. PubMed ID: 24348883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The medical profession and the pharmaceutical industry: when will we open our eyes?
    Breen KJ
    Med J Aust; 2004 Apr; 180(8):409-10. PubMed ID: 15089732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Code of conduct for psychiatrist - established on behalf of the Austrian Society for Psychiatry and Psychotherapy].
    Hinterhuber vH; Lehofer M; Ofner H; Stuppäck C;
    Neuropsychiatr; 2009; 23(4):263-6. PubMed ID: 19909698
    [No Abstract]   [Full Text] [Related]  

  • 36. Sponsored medical education?
    Nagral S
    Issues Med Ethics; 1998 Jan; 6(1):3. PubMed ID: 16267919
    [No Abstract]   [Full Text] [Related]  

  • 37. "Evidence-debased medicine" and the integrity of the medical profession.
    Elliott RL
    J Clin Ethics; 2011; 22(1):71-3. PubMed ID: 21595357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual wariness needed to spot biased drug research.
    Lazarus A
    Manag Care; 2005 Sep; 14(9):8, 13. PubMed ID: 16238253
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug maker's efforts to compete in lucrative insulin market are under scrutiny.
    Harris G; Pear R
    N Y Times Web; 2006 Jan; ():A14. PubMed ID: 16453399
    [No Abstract]   [Full Text] [Related]  

  • 40. The invisible influence of industry inducements.
    Rhodes R; Capozzi JD
    Am J Bioeth; 2003; 3(3):65-7. PubMed ID: 14594501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.